San Diego-based Viking Therapeutics marked itself as a significant competitor from the weight loss drug market in February just after revealing promising info from the mid-stage demo of experimental drug VK2735, which advised it rivaled—and outperformed—Novo and Lilly drugs when presented as being a weekly injection and in March the company unv